{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:03:06Z","timestamp":1790251386598,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-024-11793-4","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T13:15:08Z","timestamp":1730294108000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cost-effectiveness analysis of emergency department-based hepatitis C screening and linkage-to-care program"],"prefix":"10.1186","volume":"24","author":[{"given":"Sun A","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kandavadivu","family":"Umashankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Maheswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle T","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Odishoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet Y","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R","family":"Touchette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"issue":"3","key":"11793_CR1","doi-asserted-by":"publisher","first-page":"e427","DOI":"10.1097\/TXD.0000000000000866","volume":"5","author":"NF Parrish","year":"2019","unstructured":"Parrish NF, Feurer ID, Matsuoka LK, Rega SA, Perri R, Alexopoulos SP. The changing Face of Liver Transplantation in the United States: the Effect of HCV antiviral eras on Transplantation trends and outcomes. Transpl Direct. 2019;5(3):e427.","journal-title":"Transpl Direct"},{"key":"11793_CR2","unstructured":"Testing Recommendations for Hepatitis C Virus Infection | CDC. 2021. https:\/\/www.cdc.gov\/hepatitis\/hcv\/guidelinesc.htm.  Cited 2022 Dec 12."},{"key":"11793_CR3","doi-asserted-by":"publisher","unstructured":"Zou B, Yeo YH, Le MH, Henry L, Chang ET, Lok AS, Cheung R, Nguyen MH. Prevalence of Viremic Hepatitis C Virus Infection by Age, Race\/Ethnicity, and Birthplace and Disease Awareness Among Viremic Persons in the United States, 1999-2016. J Infect Dis. 2020;221(3):408\u201318. https:\/\/doi.org\/10.1093\/infdis\/jiz479.","DOI":"10.1093\/infdis\/jiz479"},{"key":"11793_CR4","unstructured":"NCD - Screening for Hepatitis C Virus (HCV). in Adults (210.13). https:\/\/www.cms.gov\/medicare-coverage-database\/view\/ncd.aspx?NCDId=361&ncdver=1&NCAId=272&NcaName=Screening+for+Hepatitis+C+Virus+(HCV)+in+Adults&ncd_id=20.7&ncd_version=8&basket=ncd%25253A20.7%25253A8%25253APercutaneous&bc=gABAAAAAAgAAAA%3D%3D&. Cited 2022 Dec 12."},{"issue":"8","key":"11793_CR5","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1093\/cid\/ciy803","volume":"68","author":"EU Patel","year":"2019","unstructured":"Patel EU, Mehta SH, Boon D, Quinn TC, Thomas DL, Tobian AAR. Limited Coverage of Hepatitis C Virus Testing in the United States, 2013\u20132017. Clin Infect Dis off Publ Infect Dis Soc Am. 2019;68(8):1402\u20135.","journal-title":"Clin Infect Dis off Publ Infect Dis Soc Am"},{"issue":"8","key":"11793_CR6","first-page":"369","volume":"25","author":"AC Moorman","year":"2019","unstructured":"Moorman AC, Xing J, Rupp LB, Gordon SC, Lu M, Spradling PR, et al. Late diagnosis of hepatitis C virus infection, 2014\u20132016: continuing missed intervention opportunities. Am J Manag Care. 2019;25(8):369\u201374.","journal-title":"Am J Manag Care"},{"issue":"6","key":"11793_CR7","doi-asserted-by":"publisher","first-page":"e0233927","DOI":"10.1371\/journal.pone.0233927","volume":"15","author":"ES Anderson","year":"2020","unstructured":"Anderson ES, Russell C, Basham K, Montgomery M, Lozier H, Crocker A, et al. High prevalence of injection drug use and blood-borne viral infections among patients in an urban emergency department. Page K, editor. PLOS ONE. 2020;15(6):e0233927.","journal-title":"PLOS ONE."},{"key":"11793_CR8","unstructured":"Consolidated Health Economic Evaluation Reporting Standards 2022. (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations - PubMed.https:\/\/pubmed.ncbi.nlm.nih.gov\/35031096\/. Cited 2024 May 4."},{"issue":"1","key":"11793_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1093\/pubmed\/fdaa276","volume":"44","author":"J Lin","year":"2022","unstructured":"Lin J, Mauntel-Medici C, Maheswaran AB, Baghikar S, Pugach O, Stein EM, et al. Factors predicting staging and treatment initiation for patients with chronic hepatitis C infection: insurance a key predictor. J Public Health Oxf Engl. 2022;44(1):148\u201357.","journal-title":"J Public Health Oxf Engl"},{"issue":"7","key":"11793_CR10","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s12325-018-0721-1","volume":"35","author":"VV Chirikov","year":"2018","unstructured":"Chirikov VV, Marx SE, Manthena SR, Strezewski JP, Saab S. Development of a Comprehensive dataset of Hepatitis C patients and examination of Disease Epidemiology in the United States, 2013\u20132016. Adv Ther. 2018;35(7):1087\u2013102.","journal-title":"Adv Ther"},{"key":"11793_CR11","unstructured":"ARCHITECT ANTI-HCV ASSAY; ARCHITECT ANTI-HCV, CALIBRATOR; ARCHITECT, ANTI-HCV CONTROL 510. (k) FDA Approval. https:\/\/fda.report\/PMA\/P050042. Cited 2022 Dec 12."},{"key":"11793_CR12","unstructured":"COBAS\u00ae AmpliPrep\/COBAS\u00ae TaqMan\u00ae HCV. Test, v2.0: Qualitative and Quantitative. Diagnostics. https:\/\/diagnostics.roche.com\/global\/en\/products\/params\/cobas-ampliprep-cobas-taqman-hcv-test-v2-0-qualitative-and-quantitative.html. Cited 2022 Dec 12."},{"issue":"8","key":"11793_CR13","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1093\/infdis\/jiw332","volume":"214","author":"M Zeremski","year":"2016","unstructured":"Zeremski M, Dimova RB, Pillardy J, de Jong YP, Jacobson IM, Talal AH. Fibrosis progression in patients with chronic Hepatitis C virus infection. J Infect Dis. 2016;214(8):1164\u201370.","journal-title":"J Infect Dis"},{"issue":"11","key":"11793_CR14","doi-asserted-by":"publisher","first-page":"e027491","DOI":"10.1136\/bmjopen-2018-027491","volume":"9","author":"A Erman","year":"2019","unstructured":"Erman A, Krahn MD, Hansen T, Wong J, Bielecki JM, Feld JJ, et al. Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update. BMJ Open. 2019;9(11):e027491.","journal-title":"BMJ Open"},{"issue":"3","key":"11793_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/cid\/civ860","volume":"62","author":"F Xu","year":"2016","unstructured":"Xu F, Moorman AC, Tong X, Gordon SC, Rupp LB, Lu M, et al. All-cause mortality and progression risks to hepatic decompensation and Hepatocellular Carcinoma in patients infected with Hepatitis C Virus. Clin Infect Dis off Publ Infect Dis Soc Am. 2016;62(3):289\u201397.","journal-title":"Clin Infect Dis off Publ Infect Dis Soc Am"},{"issue":"5","key":"11793_CR16","doi-asserted-by":"publisher","first-page":"e0197117","DOI":"10.1371\/journal.pone.0197117","volume":"13","author":"P Axley","year":"2018","unstructured":"Axley P, Mudumbi S, Sarker S, Kuo YF, Singal AK. Patients with stage 3 compared to stage 4 liver fibrosis have lower frequency of and longer time to liver disease complications. PLoS ONE. 2018;13(5):e0197117.","journal-title":"PLoS ONE"},{"issue":"11","key":"11793_CR17","doi-asserted-by":"publisher","first-page":"e0187344","DOI":"10.1371\/journal.pone.0187344","volume":"12","author":"MA Konerman","year":"2017","unstructured":"Konerman MA, Lu D, Zhang Y, Thomson M, Zhu J, Verma A, et al. Assessing risk of fibrosis progression and liver-related clinical outcomes among patients with both early stage and advanced chronic hepatitis C. PLoS ONE. 2017;12(11):e0187344.","journal-title":"PLoS ONE"},{"issue":"3","key":"11793_CR18","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1002\/hep.30303","volume":"69","author":"H Park","year":"2019","unstructured":"Park H, Wang W, Henry L, Nelson DR. Impact of all-oral direct-acting antivirals on clinical and economic outcomes in patients with chronic Hepatitis C in the United States. Hepatol Baltim Md. 2019;69(3):1032\u201345.","journal-title":"Hepatol Baltim Md"},{"issue":"2","key":"11793_CR19","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/hep.24370","volume":"54","author":"JL Dienstag","year":"2011","unstructured":"Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatol Baltim Md. 2011;54(2):396\u2013405.","journal-title":"Hepatol Baltim Md"},{"issue":"7","key":"11793_CR20","doi-asserted-by":"publisher","first-page":"e2011055","DOI":"10.1001\/jamanetworkopen.2020.11055","volume":"3","author":"Y Kalidindi","year":"2020","unstructured":"Kalidindi Y, Jung J, Feldman R, Riley T. Association of Direct-Acting Antiviral Treatment with Mortality among Medicare beneficiaries with Hepatitis C. JAMA Netw Open. 2020;3(7):e2011055.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"11793_CR21","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/jvh.12538","volume":"23","author":"M Lu","year":"2016","unstructured":"Lu M, Li J, Rupp LB, Holmberg SD, Moorman AC, Spradling PR, et al. Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma. J Viral Hepat. 2016;23(9):718\u201329.","journal-title":"J Viral Hepat"},{"issue":"9","key":"11793_CR22","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/jvh.13543","volume":"28","author":"SA McDonald","year":"2021","unstructured":"McDonald SA, Barclay ST, Innes HA, Fraser A, Hayes PC, Bathgate A, et al. Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality. J Viral Hepat. 2021;28(9):1246\u201355.","journal-title":"J Viral Hepat"},{"issue":"7","key":"11793_CR23","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/apt.15464","volume":"50","author":"S Gawrieh","year":"2019","unstructured":"Gawrieh S, Dakhoul L, Miller E, Scanga A, deLemos A, Kettler C, et al. Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study. Aliment Pharmacol Ther. 2019;50(7):809\u201321.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"11793_CR24","doi-asserted-by":"publisher","first-page":"ofy144","DOI":"10.1093\/ofid\/ofy144","volume":"5","author":"MS Moore","year":"2018","unstructured":"Moore MS, Bocour A, Tran OC, Qiao B, Schymura MJ, Laraque F, et al. Effect of Hepatocellular Carcinoma on Mortality among individuals with Hepatitis B or Hepatitis C Infection in New York City, 2001\u20132012. Open Forum Infect Dis. 2018;5(7):ofy144.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"11793_CR25","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.hpb.2020.07.012","volume":"23","author":"MK Turgeon","year":"2021","unstructured":"Turgeon MK, Lee RM, Gamboa AC, Yopp A, Ryon EL, Goel N, et al. Impact of hepatitis C treatment on long-term outcomes for patients with hepatocellular carcinoma: a United States Safety Net Collaborative Study. HPB. 2021;23(3):422\u201333.","journal-title":"HPB"},{"issue":"10","key":"11793_CR26","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/hpb.12134","volume":"15","author":"RT Groeschl","year":"2013","unstructured":"Groeschl RT, Hong JC, Christians KK, Turaga KK, Tsai S, Pilgrim CHC, et al. Viral status at the time of liver transplantation for hepatocellular carcinoma: a modern predictor of longterm survival. HPB. 2013;15(10):794\u2013802.","journal-title":"HPB"},{"issue":"4","key":"11793_CR27","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1053\/j.gastro.2018.07.008","volume":"155","author":"D Kim","year":"2018","unstructured":"Kim D, Li AA, Gadiparthi C, Khan MA, Cholankeril G, Glenn JS, et al. Changing trends in etiology-based Annual Mortality from Chronic Liver Disease, from 2007 through 2016. Gastroenterology. 2018;155(4):1154\u2013e11633.","journal-title":"Gastroenterology"},{"key":"11793_CR28","unstructured":"Products - Life Tables - Homepage. 2022. https:\/\/www.cdc.gov\/nchs\/products\/life_tables.htm.  Cited 2022 Dec 12."},{"issue":"10","key":"11793_CR29","first-page":"2341","volume":"41","author":"P Huang","year":"2021","unstructured":"Huang P, Wang Y, Yue M, Ge Z, Xia X, Jeyarajan AJ, et al. The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: a comprehensive analysis. Liver Int off J Int Assoc Study Liver. 2021;41(10):2341\u201357.","journal-title":"Liver Int off J Int Assoc Study Liver"},{"issue":"4","key":"11793_CR30","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jhep.2019.11.012","volume":"72","author":"B Hajarizadeh","year":"2020","unstructured":"Hajarizadeh B, Cunningham EB, Valerio H, Martinello M, Law M, Janjua NZ, et al. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: a meta-analysis. J Hepatol. 2020;72(4):643\u201357.","journal-title":"J Hepatol"},{"issue":"5","key":"11793_CR31","doi-asserted-by":"publisher","first-page":"e0215596","DOI":"10.1371\/journal.pone.0215596","volume":"14","author":"S Cossais","year":"2019","unstructured":"Cossais S, Schwarzinger M, Pol S, Fontaine H, Larrey D, Pageaux GP, et al. Quality of life in patients with chronic hepatitis C infection: severe comorbidities and disease perception matter more than liver-disease stage. PLoS ONE. 2019;14(5):e0215596.","journal-title":"PLoS ONE"},{"issue":"1","key":"11793_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jval.2019.07.005","volume":"23","author":"YA Saeed","year":"2020","unstructured":"Saeed YA, Phoon A, Bielecki JM, Mitsakakis N, Bremner KE, Abrahamyan L, et al. A systematic review and Meta-analysis of Health utilities in patients with chronic Hepatitis C. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2020;23(1):127\u201337.","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"issue":"6","key":"11793_CR33","first-page":"1477","volume":"28","author":"R Juanbeltz","year":"2019","unstructured":"Juanbeltz R, Castilla J, Mart\u00ednez-Baz I, O\u2019Leary A, Sarobe M, San Miguel R. Health-related quality of life in hepatitis C patients who achieve sustained virological response to direct-acting antivirals: a comparison with the general population. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2019;28(6):1477\u201384.","journal-title":"Qual Life Res Int J Qual Life Asp Treat Care Rehabil"},{"issue":"3","key":"11793_CR34","first-page":"803","volume":"30","author":"R Jiang","year":"2021","unstructured":"Jiang R, Janssen MFB, Pickard AS. US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2021;30(3):803\u201316.","journal-title":"Qual Life Res Int J Qual Life Asp Treat Care Rehabil"},{"issue":"2","key":"11793_CR35","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jhep.2018.03.007","volume":"69","author":"M Puoti","year":"2018","unstructured":"Puoti M, Foster GR, Wang S, Mutimer D, Gane E, Moreno C, et al. High SVR12 with 8-week and 12-week glecaprevir\/pibrentasvir therapy: an integrated analysis of HCV genotype 1\u20136 patients without cirrhosis. J Hepatol. 2018;69(2):293\u2013300.","journal-title":"J Hepatol"},{"issue":"8","key":"11793_CR36","first-page":"1841","volume":"40","author":"A Mangia","year":"2020","unstructured":"Mangia A, Milligan S, Khalili M, Fagiuoli S, Shafran SD, Carrat F, et al. Global real-world evidence of sofosbuvir\/velpatasvir as simple, effective HCV treatment: analysis of 5552 patients from 12 cohorts. Liver Int off J Int Assoc Study Liver. 2020;40(8):1841\u201352.","journal-title":"Liver Int off J Int Assoc Study Liver"},{"issue":"10","key":"11793_CR37","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1093\/cid\/ciz022","volume":"69","author":"E Gane","year":"2019","unstructured":"Gane E, Poordad F, Zadeikis N, Valdes J, Lin CW, Liu W, et al. Safety and pharmacokinetics of Glecaprevir\/Pibrentasvir in adults with chronic genotype 1\u20136 Hepatitis C Virus infections and compensated Liver Disease. Clin Infect Dis off Publ Infect Dis Soc Am. 2019;69(10):1657\u201364.","journal-title":"Clin Infect Dis off Publ Infect Dis Soc Am"},{"issue":"27","key":"11793_CR38","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","volume":"373","author":"MP Curry","year":"2015","unstructured":"Curry MP, O\u2019Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618\u201328.","journal-title":"N Engl J Med"},{"issue":"22","key":"11793_CR39","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","volume":"376","author":"M Bourli\u00e8re","year":"2017","unstructured":"Bourli\u00e8re M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376(22):2134\u201346.","journal-title":"N Engl J Med"},{"issue":"7","key":"11793_CR40","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1093\/cid\/ciy220","volume":"67","author":"JK Rockstroh","year":"2018","unstructured":"Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, et al. Efficacy and safety of Glecaprevir\/Pibrentasvir in patients coinfected with Hepatitis C Virus and Human Immunodeficiency Virus Type 1: the EXPEDITION-2 study. Clin Infect Dis off Publ Infect Dis Soc Am. 2018;67(7):1010\u20137.","journal-title":"Clin Infect Dis off Publ Infect Dis Soc Am"},{"issue":"1","key":"11793_CR41","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/cid\/cix260","volume":"65","author":"D Wyles","year":"2017","unstructured":"Wyles D, Br\u00e4u N, Kottilil S, Daar ES, Ruane P, Workowski K, et al. Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in patients coinfected with human immunodeficiency virus type 1: an Open-Label, phase 3 study. Clin Infect Dis off Publ Infect Dis Soc Am. 2017;65(1):6\u201312.","journal-title":"Clin Infect Dis off Publ Infect Dis Soc Am"},{"issue":"1","key":"11793_CR42","doi-asserted-by":"publisher","first-page":"e0208506","DOI":"10.1371\/journal.pone.0208506","volume":"14","author":"GR Foster","year":"2019","unstructured":"Foster GR, Asselah T, Kopecky-Bromberg S, Lei Y, Asatryan A, Trinh R, et al. Safety and efficacy of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older. PLoS ONE. 2019;14(1):e0208506.","journal-title":"PLoS ONE"},{"issue":"11","key":"11793_CR43","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/cid\/ciw579","volume":"63","author":"J Grebely","year":"2016","unstructured":"Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, Han L, et al. Efficacy and safety of Sofosbuvir\/Velpatasvir in patients with chronic Hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials. Clin Infect Dis off Publ Infect Dis Soc Am. 2016;63(11):1479\u201381.","journal-title":"Clin Infect Dis off Publ Infect Dis Soc Am"},{"issue":"4","key":"11793_CR44","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/hep.28430","volume":"63","author":"DB Rein","year":"2016","unstructured":"Rein DB, Borton J, Liffmann DK, Wittenborn JS. The burden of hepatitis C to the United States Medicare system in 2009: descriptive and economic characteristics. Hepatol Baltim Md. 2016;63(4):1135\u201344.","journal-title":"Hepatol Baltim Md"},{"issue":"7","key":"11793_CR45","first-page":"531","volume":"17","author":"C McAdam-Marx","year":"2011","unstructured":"McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm JMCP. 2011;17(7):531\u201346.","journal-title":"J Manag Care Pharm JMCP"},{"key":"11793_CR46","unstructured":"Micromedex RED, BOOK - Micromedex RED BOOK. 2022. https:\/\/www.ibm.com\/products\/micromedex-red-book. Cited 2022 Dec 12."},{"key":"11793_CR47","unstructured":"The Use of Medicines in the U.S. - IQVIA. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/the-use-of-medicines-in-the-us. Cited 2022 Dec 12."},{"key":"11793_CR48","unstructured":"BEA Interactive Data Application. https:\/\/apps.bea.gov\/iTable\/?reqid=19&step=2&isuri=1&categories=survey#eyJhcHBpZCI6MTksInN0ZXBzIjpbMSwyLDNdLCJkYXRhIjpbWyJjYXRlZ29yaWVzIiwiU3VydmV5Il0sWyJOSVBBX1RhYmxlX0xpc3QiLCI2NCJdXX0=. Cited 2022 Dec 12."},{"key":"11793_CR49","unstructured":"Clinical Laboratory Fee Schedule Files. | CMS. https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/ClinicalLabFeeSched\/Clinical-Laboratory-Fee-Schedule-Files. Cited 2022 Dec 12."},{"key":"11793_CR50","unstructured":"Recommendations for Testing, Managing, and, Treating Hepatitis C. | HCV Guidance. https:\/\/www.hcvguidelines.org\/. Cited 2022 Dec 12."},{"issue":"9","key":"11793_CR51","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","volume":"371","author":"PJ Neumann","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796\u20137.","journal-title":"N Engl J Med"},{"key":"11793_CR52","unstructured":"Screen all adult patients for hepatitis C | CDC. 2023. https:\/\/www.cdc.gov\/knowmorehepatitis\/hcp\/Screen-All-Patients-For-HepC.htm. Cited 2023 Jun 16."},{"issue":"10","key":"11793_CR53","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1002\/cam4.2247","volume":"8","author":"ML Kasting","year":"2019","unstructured":"Kasting ML, Giuliano AR, Reich RR, Duong LM, Rathwell J, Roetzheim RG, et al. Electronic medical record-verified hepatitis C virus screening in a large health system. Cancer Med. 2019;8(10):4555\u201364.","journal-title":"Cancer Med"},{"issue":"3","key":"11793_CR54","doi-asserted-by":"publisher","first-page":"e000577","DOI":"10.1136\/bmjoq-2018-000577","volume":"8","author":"S Bakhai","year":"2019","unstructured":"Bakhai S, Nallapeta N, El-Atoum M, Arya T, Reynolds JL. Improving hepatitis C screening and diagnosis in patients born between 1945 and 1965 in a safety-net primary care clinic. BMJ Open Qual. 2019;8(3):e000577.","journal-title":"BMJ Open Qual"},{"issue":"2","key":"11793_CR55","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s11606-019-05536-z","volume":"35","author":"L Hojat","year":"2020","unstructured":"Hojat L, Avery A, Greco PJ, Kaelber DC. Doubling Hepatitis C Virus Screening in Primary Care using Advanced Electronic Health Record Tools-A Non-randomized Controlled Trial. J Gen Intern Med. 2020;35(2):498\u2013504.","journal-title":"J Gen Intern Med"},{"issue":"6","key":"11793_CR56","first-page":"1107","volume":"137","author":"H King","year":"2022","unstructured":"King H, Soh JE, Thompson WW, Brown JR, Rapposelli K, Vellozzi C. Testing for Hepatitis C virus infection among adults aged\u2009\u2265\u200918 in the United States, 2013\u20132017. Public Health Rep Wash DC 1974. 2022;137(6):1107\u201317.","journal-title":"Public Health Rep Wash DC 1974"},{"issue":"3","key":"11793_CR57","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/hep.27410","volume":"61","author":"JW Galbraith","year":"2015","unstructured":"Galbraith JW, Franco RA, Donnelly JP, Rodgers JB, Morgan JM, Viles AF, et al. Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department. Hepatol Baltim Md. 2015;61(3):776\u201382.","journal-title":"Hepatol Baltim Md"},{"issue":"4","key":"11793_CR58","doi-asserted-by":"publisher","first-page":"ofy065","DOI":"10.1093\/ofid\/ofy065","volume":"5","author":"JK Cornett","year":"2018","unstructured":"Cornett JK, Bodiwala V, Razuk V, Shukla D, Narayanan N. Results of a Hepatitis C Virus Screening Program of the 1945\u20131965 birth cohort in a large Emergency Department in New Jersey. Open Forum Infect Dis. 2018;5(4):ofy065.","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"11793_CR59","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1111\/acem.13484","volume":"25","author":"EM Schechter-Perkins","year":"2018","unstructured":"Schechter-Perkins EM, Miller NS, Hall J, Hartman JJ, Dorfman DH, Andry C, et al. Implementation and Preliminary Results of an Emergency Department Nontargeted, Opt-out Hepatitis C Virus Screening Program. Kuehl DR,\u00a0editor. Acad Emerg Med. 2018;25(11):1216\u201326.","journal-title":"Acad Emerg Med."},{"issue":"3","key":"11793_CR60","first-page":"379","volume":"82","author":"L Opstaele","year":"2019","unstructured":"Opstaele L, Bielen R, Bourgeois S, Moreno C, Nevens F, Robaeys G, et al. Who to screen for hepatitis C? A cost-effectiveness study in Belgium of comprehensive hepatitis C screening in four target groups. Acta Gastro-Enterol Belg. 2019;82(3):379\u201387.","journal-title":"Acta Gastro-Enterol Belg"},{"issue":"8","key":"11793_CR61","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jval.2020.03.014","volume":"23","author":"J Williams","year":"2020","unstructured":"Williams J, Vickerman P, Douthwaite S, Nebbia G, Hunter L, Wong T, et al. An economic evaluation of the cost-effectiveness of opt-out Hepatitis B and Hepatitis C Testing in an Emergency Department setting in the United Kingdom. Value Health. 2020;23(8):1003\u201311.","journal-title":"Value Health"},{"issue":"6","key":"11793_CR62","first-page":"1282","volume":"40","author":"AB Mendlowitz","year":"2020","unstructured":"Mendlowitz AB, Naimark D, Wong WWL, Capraru C, Feld JJ, Isaranuwatchai W, et al. The emergency department as a setting-specific opportunity for population-based hepatitis C screening: an economic evaluation. Liver Int off J Int Assoc Study Liver. 2020;40(6):1282\u201391.","journal-title":"Liver Int off J Int Assoc Study Liver"},{"key":"11793_CR63","unstructured":"Policy (OIDP) O of ID and H, editor. Viral Hepatitis. HHS.gov. 2016. https:\/\/www.hhs.gov\/hepatitis\/index.html. Cited 2022 Dec 12."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-024-11793-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-024-11793-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-024-11793-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T13:26:41Z","timestamp":1730294801000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-024-11793-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["11793"],"URL":"https:\/\/doi.org\/10.1186\/s12913-024-11793-4","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]},"assertion":[{"value":"24 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the University of Illinois at Chicago Institutional Review Board (IRB ID: STUDY2020-0169-MOD002). Authors used the summary data from Project HEAL to build an economic model and did not have access to information that could identify individual participants during or after data collection. Informed consent was waived and not required as approved by the UIC. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Daniel R Touchette is the Senior Scientific Advisor for Monument Analytics, a consultant for Astra Zeneca, and has received research funding from AbbVie, Inc and Takeda awarded to University of Illinois Chicago for work unrelated to this study. Sun A Choi was the post-doctoral fellow at University of Illinois Chicago, funded by Takeda and currently is a consultant at Cobbs Creek Healthcare. Kandavadivu Umashankar was a post-doctoral fellow at University of Illinois at Chicago, funded by Takeda and currently has a contractor role at AbbVie, Inc. Michelle Martin has served on advisory boards and serves on the speakers\u2019 bureaus for AbbVie and Gilead, has received grant funding from Merck and Gilead, and is a minor shareholder for AbbVie, Gilead, and Merck. Janet Y Lin has received funding previously from Gilead to implement routine HCV screening in an emergency department setting at University of Illinois Chicago. Anjana Maheswaran, Jean Lee, and Matt Odishoo do not have competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1308"}}